The Impact of Cryoballoon Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation on Healthcare Utilization and Costs: An Economic Analysis From the FIRE AND ICE Trial by Chun KRJ et al.
The Impact of Cryoballoon Versus Radiofrequency Ablation for
Paroxysmal Atrial Fibrillation on Healthcare Utilization and
Costs: An Economic Analysis From the FIRE AND ICE Trial
K. R. Julian Chun, MD; Josep Brugada, MD; Arif Elvan, MD; Laszlo Geller, MD; Matthias Busch, MD; Alberto Barrera, MD;
Richard J. Schilling, MD; Matthew R. Reynolds, MD; Robert B. Hokanson, BA; Reece Holbrook, BSEE; Benedict Brown, MBA;
Michael Schl€uter, PhD; Karl-Heinz Kuck, MD; for the FIRE AND ICE Investigators*
Background-—This study sought to assess payer costs following cryoballoon or radiofrequency current (RFC) catheter ablation of
paroxysmal atrial fibrillation in the randomized FIRE AND ICE trial.
Methods and Results-—A trial period analysis of healthcare costs evaluated the impact of ablation modality (cryoballoon versus
RFC) on differences in resource use and associated payer costs. Analyses were based on repeat interventions, rehospitalizations,
and cardioversions during the trial, with unit costs based on 3 national healthcare systems (Germany [€], the United Kingdom [£],
and the United States [$]). Total payer costs were calculated by applying standard unit costs to hospital stays, using International
Classification of Diseases, 10th Revision diagnoses and procedure codes that were mapped to country-specific diagnosis-related
groups. Patients (N=750) randomized 1:1 to cryoballoon (n=374) or RFC (n=376) ablation were followed for a mean of 1.5 years.
Resource use was lower in the cryoballoon than the RFC group (205 hospitalizations and/or interventions in 122 patients versus
268 events in 154 patients). The cost differences per patient in mean total payer costs during follow-up were €640, £364, and
$925 in favor of cryoballoon ablation (P=0.012, 0.013, and 0.016, respectively). This resulted in trial period total cost savings of
€245 000, £140 000, and $355 000.
Conclusions-—When compared with RFC ablation, cryoballoon ablation was associated with a reduction in resource use and payer
costs. In all 3 national healthcare systems analyzed, this reduction resulted in substantial trial period cost savings, primarily
attributable to fewer repeat ablations and a reduction in cardiovascular rehospitalizations with cryoballoon ablation.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Identifier: NCT01490814. ( J Am Heart Assoc. 2017;6:e006043.
DOI: 10.1161/JAHA.117.006043.)
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A trial fibrillation (AF) is a common and chronic cardiacarrhythmia that is a burden to patients and the healthcare
system, with an estimated annual cost of €660 million to the
German healthcare system,1 1% of the National Health Service
budget in the United Kingdom,2 and $6 billion in the US
healthcare system.3 Pulmonary vein isolation (PVI) by way of
catheter ablation has been proven to be an effective treatment
option for patients with symptomatic paroxysmal AF. However,
despite a class I indication in guidelines,4,5 only a minority of
patients who are indicated receive AF ablation therapy.6
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The FIRE AND ICE study is the largest randomized trial to
compare the efficacy and safety of PVI in patients with drug-
refractory symptomatic paroxysmal AF, using either the
“single-shot” cryoballoon or the point-by-point radiofrequency
current (RFC) methodology. Results for primary and sec-
ondary study end points have been previously reported.7,8 The
trial met the primary safety and efficacy end points and
confirmed that cryoballoon ablation was noninferior to RFC
ablation when assessed by the time to first documented
clinical failure (recurrence of AF lasting for >30 seconds,
occurrence of atrial flutter/tachycardia, use of antiarrhythmic
drugs, or repeat ablation) following a 90-day blanking period.7
In the secondary end point analysis, comprehensive trial
period reinterventions, rehospitalizations, and quality-of-life
measures were evaluated. While the average quality-of-life
scores improved to a similar extent in both groups, patients
who underwent PVI with the cryoballoon demonstrated: (1) a
21% reduction in all-cause rehospitalizations; (2) a 34%
reduction in cardiovascular rehospitalizations; (3) a 33%
reduction in repeat ablations; and (4) a 50% reduction in
direct-current cardioversions.8
This reduction in clinically relevant events during follow-up
after PVI not only reflects a reduced AF burden in the
cryoballoon group, it may also have a significant impact on
healthcare costs when the 2 technologies are compared.
There is a growing need to make transparent assessments of
the value of healthcare interventions, balancing costs with
health outcomes.9 Consequently, in this report, we present a
trial period economic analysis to better understand the
differential cost between cryoballoon and RFC ablation from
the perspective of a payer. The analyses were performed
across national reimbursement systems in 3 different coun-
tries to explore whether reductions in resource use, specif-
ically, rehospitalizations, reinterventions, and cardioversions,
result in similar cost differences in each country.
Methods
Study Design and Patient Population
FIRE AND ICE (ClinicalTrials.gov Identifier: NCT01490814)
was a controlled, prospective, randomized, noninferiority,
blinded-outcomes, parallel-group trial designed to evaluate
PVI using cryoballoon or RFC catheter ablation for the
treatment of symptomatic, drug-refractory, paroxysmal AF.
The study was conducted in 16 centers in 8 European
countries. The design, primary end points, secondary end
points, secondary analyses, and procedural techniques have
been previously published.7,8,10 After approval from each
center’s respective ethics committee, written informed con-
sent was obtained from each patient before 1:1 randomization
to either cryoballoon ablation (the Arctic Front family of
cryoballoon catheters) or RFC catheter ablation (the Thermo-
Cool family of RFC catheters). Patients aged between 18 and
75 years were required to have at least 2 episodes of
symptomatic drug-refractory paroxysmal AF, 1 episode of
documented paroxysmal AF in the previous 12 months, and at
least one treatment failure with a membrane-active antiar-
rhythmic drug. Major exclusion criteria included prior left
atrial ablation, a left atrial diameter >55 mm, stroke within
the past 6 months, any cardiac surgery or intervention, or
myocardial infarction within 3 months of enrollment.
Economic Analysis
The primary efficacy and safety analyses for FIRE AND ICE
demonstrated no significant differences between RFC and
cryoballoon ablation, and no significant differences were
observed in the quality-of-life data from the secondary
analyses. Therefore, a trial period economic analysis from a
payer perspective was selected as the most appropriate type
of economic evaluation (as opposed to a cost-effectiveness
analysis). The analysis was performed across healthcare
Clinical Perspective
What Is New?
• Pulmonary vein isolation using cryoballoon ablation resulted
in a significant reduction in trial period healthcare payer
costs and resource utilization in 3 national healthcare
systems when compared with patients treated with
radiofrequency current catheter ablation.
• Trial period healthcare cost savings per patient in the 3
systems analyzed were: Germany=€640, the United King-
dom=£364, and the United States=$925, in favor of
cryoballoon compared with radiofrequency current.
• Reduction in payer costs associated with pulmonary vein
isolation using cryoballoon is driven by the reductions in
repeat ablations and cardiovascular rehospitalizations in
patients treated with cryoballoon versus radiofrequency
current.
What Are the Clinical Implications?
• Pulmonary vein isolation using cryoballoon resulted in
decreased atrial fibrillation healthcare disease burden and
symptoms and fewer reinterventions, with significant clinical
and economic impact.
• Healthcare and resource cost savings in patients with drug-
refractory paroxysmal atrial fibrillation were demonstrated
across multiple diverse healthcare systems.
• The implications on daily clinical practice and healthcare
costs should be an important consideration for the
optimization of patient outcomes with maximum efficiency
given the imperative for improving value-based health care.
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systems in Germany, the United Kingdom, and the United
States. Electronic case report forms captured detailed
resource utilization, hereafter referred to as healthcare
utilization (HCU) data during the trial period. Specifically, all-
cause rehospitalization, cardiovascular rehospitalizations (AF
related and non–AF related), repeat ablations, and direct
current/pharmacological cardioversions were required to be
reported and are included in this analysis. The aforementioned
categories analyzed were not unique outcomes/end points of
the study. Repeat ablation and cardioversions were unique
outcomes, but “other cardiovascular rehospitalizations” and
“noncardiovascular hospitalizations” are post hoc aggrega-
tions of numerous hospitalization episodes. Treatment details
for each HCU during the trial follow-up period were evaluated.
Diagnosis and procedure codes from the International Statis-
tical Classification of Diseases and Related Health Problems,
10th Revision (ICD-10) were retrospectively assigned in a
bottom-up assignment of 473 resource utilizations by a
professional coder who was blinded to the therapy random-
ization but had full access to the study HCU data. ICD-10
codes were assigned to each event, independent of the
treatment group, to facilitate the assignment of diagnosis-
related group (DRG) payment codes for each respective
country. Data were further evaluated to identify the unique
hospital stays (which is of relevance to payers). For example,
a cardioversion completed as part of a hospital stay is costed
within a single DRG payment. The most recently available
payment rate for each DRG (>80 unique DRGs assigned) was
applied and the respective utilization categorized as: (1) all-
cause rehospitalization; (2) cardiovascular rehospitalizations
(AF related and non–AF related); (3) repeat ablations; and (4)
cardioversions. Costs related to the index ablation hospital
stay were not included in this utilization and cost analysis for
pragmatic reasons. First, payer costs incurred for the index
ablation are equivalent and analyses including index ablation
procedure/hospitalization costs would not change the results
of the analysis. Further supporting this approach, the trial
found no significant difference between the 2 technologies
with regard to serious procedure-related adverse events,
which suggests no meaningful difference in payer costs
specific to the treatment of adverse events.
HCU Payments in Germany
The utilization and cost analysis for Germany used G-DRG
Version 2016. The online DRG grouper software was used to
select the appropriate DRG for each hospital stay. In the
cases where the appropriate DRG codes were subdivided
according to comorbidities and complications (eg, with and
without major comorbidities and complications), the number
of hospitalizations per category per year were obtained and
the weighted average costs were calculated for each DRG.
Electrical cardioversions without an overnight hospital stay
were assigned a day-case tariff of €655 for DRG F71B
(nonsevere cardiac arrhythmia and conduction disturbances
without extremely severe comorbidity or complications,
without catheter-based electrophysiologic study of the heart).
Similarly, pharmacological cardioversions were assigned an
emergency department visit with a cost of €90.89, based on
fees established in the Einheitlicher Bewertungsmaßstab
catalogue of physician fees.
HCU Payments in the United Kingdom
The utilization and cost analysis for the United Kingdom used
the National Schedule of Reference Costs (year 2014–2015,
spell level data). This source was preferred to the most recent
“Payment-by-Results” tariffs, because reference costs provide
average costs per Healthcare Resource Group (HRG), includ-
ing all categories of hospitalizations (eg, day case and short
and long stay). Reference cost data are recommended for use
in economic evaluations by the National Institute for Health
and Care Excellence. Commercially available HRG Grouper
software was used to select the appropriate HRG for each
hospital stay. Reference cost data are reported for various
levels of complications and comorbidities, with the number of
hospitalizations per category per year, and the weighted
average cost was calculated for each HRG. Electrical and
pharmacological cardioversions without an overnight stay
were assigned a cost of £678 using a day-case cost for HRG
EB07 (arrhythmia or conduction disorder).
HCU Payments in the United States
For the United States, payments for trial HCUs represent the
national Medicare payment levels for the year 2016. In the case
where there was ambiguity in the data (eg, whether additional
procedures were performed or comorbidities were present
based on secondary diagnoses), the lowest acuity codes were
selected. Since billing information was not collected as part of
the original trial, it was imputed using HCU data from the case
report forms. This imputation was performed using Centers for
Medicare & Medicaid Services DRG (MS-DRG). ICD-10 principal
diagnosis and procedure codes were used to create anMS-DRG
assignment and mapped to the associated national Medicare
payments. Patients with AF are ablated in both inpatient and
outpatient settings. To be conservative, this analysis uses the
lower of the 2 payments, which is associated with the inpatient
setting.
Statistical Analyses
The number of HCUs and patients who had HCU events were
calculated within the treatment groups and subclassified by
DOI: 10.1161/JAHA.117.006043 Journal of the American Heart Association 3
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event type for the entire trial period (1.540.80 years for
patients randomized to cryoballoon ablation and
1.540.79 years for patients randomized to RFC ablation).
Costs for each HCU event were drawn from the DRG/HRG
payment assignments. Total trial period costs per patient
were calculated by summing all HCU costs across the
duration of the trial. Because costs did not have a normal
distribution (they exhibited a right skew along with a large
spike at zero), 2-sided Wilcoxon rank-sum tests with a=0.05
were used to determine whether HCU costs differed between
treatment groups. Total trial period costs are presented at the
study level and patient level, total trial costs per randomiza-
tion group, and average total trial costs per patient.
Bootstrapping statistical methods were used for the
resampling analysis to estimate the distribution of cost
difference between the 2 treatment groups. In the
bootstrap, the sample data are treated as the population.
Data are then randomly generated from the sample data to
obtain a distribution.11 Bootstrapping takes repeated sam-
ples from the data to calculate the accuracy of estimates
for the entire population. The bootstrap method was
applied by taking 1000 random resamplings with replace-
ment from the FIRE AND ICE data set, and the result is a
random variance from the original sample. The cryoballoon
and RFC groups were replicated (1000 iterations) by
resampling from the individual patient data. This was
performed for all-cause rehospitalizations and repeated for
cardiovascular rehospitalizations.
One-way sensitivity analysis was conducted using 20%
payment variance for the 4 most commonly used payment
codes, which collectively represented 61% of all hospital stays
(repeat ablation, arrhythmia-related rehospitalization, electri-
cal cardioversion, and pharmacological cardioversion).
All statistical analyses were completed using SAS 9.4
software (SAS Institute Inc).
Table 1. HCUs by Ablation Group
HCU Type
Cryoballoon
HCUs (No.
of Patients)
(n=374)
RFC HCUs
(No. of Patients)
(n=376)
Subtotal cardiovascular-related
rehospitalization
139 (88) 212 (132)
Repeat ablation 49 (44) 70 (66)
Cardiovascular rehospitalization 74 (53) 109 (80)
AF related 34 (25) 55 (48)
Non–AF related 40 (33) 54 (40)
Cardioversion 16 (13) 33 (28)
Subtotal noncardiovascular
rehospitalization
66 (49) 56 (42)
Total† 205 (122) 268 (154)
AF indicates atrial fibrillation; HCU, healthcare utilization; RFC, radiofrequency current.
†Total=subtotal cardiovascular-related rehospitalization+subtotal noncardiovascular
rehospitalization.
Table 2. Tariff/Payment Levels for the Most Common Healthcare Utilizations
List of DRGs With >5 Occurrences Germany United Kingdom United States
Arrhythmia ablation—percutaneous intracardiac procedures without MCC €9505 £5622 $14 291
AF hospitalization—cardiac arrhythmia & conduction disorders without MCC €1796 £1195 $3312
Electrical cardioversion €655 £679 $467
Pharmacological cardioversion €91 £679 $173
Esophagitis, gastrointestinal, and digestive disorders without MCC €1662 £2056 $4371
Respiratory signs and symptoms €1550 £1033 $4306
Peripheral vascular disorders without CC/MCC €2548 £2092 $4148
Syncope and collapse €1722 £1141 $4506
Simple pneumonia and pleurisy without CC/MCC €2527 £3430 $4200
Medical back problems without MCC €1971 £3732 $5108
Signs and symptoms of musculoskeletal system and connective tissue without MCC €1792 £829 $4394
Disequilibrium €1832 £1627 $3961
Bone diseases and arthropathies without MCC €2272 £1207 $4333
Atherosclerosis without MCC €1822 £2134 $3796
Hypertension without MCC €1666 £939 $3913
AF indicates atrial fibrillation; CC, complication or comorbidity; DRG, diagnosis-related group; MCC, major complications and comorbid condition.
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Results
Trial Period HCU and Costs
Patients (N=750) randomized 1:1 to cryoballoon (n=374) or
RFC (n=376) ablation were followed for a mean of 1.5 years.
As detailed in Table 1, a total of 205 HCUs were observed in
122 of the 374 patients randomized to cryoballoon ablation
and 268 HCUs were observed in 154 of the 376 patients
randomized to RFC ablation. The trial period incidence of
repeat ablations, AF-related cardiovascular rehospitalizations,
non–AF-related cardiovascular rehospitalizations, and car-
dioversions were all lower in the cryoballoon group when
compared with RFC (49 versus 70 HCUs, 34 versus 55 HCUs,
40 versus 54 HCUs, and 16 versus 33 HCUs, respectively). A
marginally higher incidence of noncardiovascular hospitaliza-
tions was observed in the cryoballoon group. The unique
healthcare system–related costs assigned to DRGs with at
least 5 occurrences during the trial period are summarized in
Table 2.
Trial Period Cost Differences
Table 3 depicts the total cost differences per patient during
the FIRE AND ICE trial period in the 3 healthcare systems
included in this analysis. Trial period costs per patient were
lower in the cryoballoon group, resulting in cost differences of
€640 (P=0.012) in Germany, £364 (P=0.013) in the United
Kingdom, and $925 (P=0.016) in the United States. These
cost differences were driven by significantly reduced costs
associated with repeat ablations and AF-related and non–AF-
related cardiovascular rehospitalizations. Figure 1 summa-
rizes the cost differentials across the 3 national healthcare
systems within the respective treatment cohorts. These per-
Table 3. Healthcare Cost Savings per Patient
Healthcare Utilization
Germany United Kingdom United States
Cryoballoon RFC Δ Cryoballoon RFC Δ Cryoballoon RFC Δ
Subtotal cardiovascular-related
rehospitalization
€1680 €2379 €700† £1103 £1523 £419† $2804 $3792 $988†
Repeat ablation €1233 €1757 €524† £726 £1036 £310† $1872 $2661 $788†
AF-related cardiovascular
rehospitalization
€196 €287 €91† £140 £195 £55† $410 $513 $103†
Non–AF-related cardiovascular
rehospitalization
€235 €298 €63 £209 £233 £24 $508 $588 $80
Cardioversion €16 €38 €22† £29 £60 £31† $14 $31 $17†
Subtotal noncardiovascular
rehospitalization
€395 €335 €-60 £360 £304 £-56 $870 $807 $-63
Total €2075 €2714 €639.51† £1464 £1827 £363.50† $3674 $4599 $924.62†
AF indicates atrial fibrillation; RFC, radiofrequency current. Total=subtotal cardiovascular-related rehospitalization+subtotal noncardiovascular rehospitalization.
†P<0.05.
Cardioversions
Non-Cardiovascular
rehospitalizations
Cardiovascular rehospitalizations
Repeat ablations1020
RFC
Germany
(€1000)
United Kingdom
(£1000)
United States
($1000)
660
219
125
460 389
160
114
134
130
271
303
325
343
700
413
1000
161
147
Cryo RFC Cryo RFC Cryo
775 686
547
1729
1374
Total Trial-Period Cost Difference by Country
Country
GER
UK
US
RFC
€1020K
£686K
$1729K
Cryoballoon
€775K
£547K
$1374K
∆
€245K
£140K
$355K
P value
0.012
0.013
0.016
Figure 1. Healthcare cost savings: Total trial period payer costs
of healthcare utilizations (HCUs) for the cryoballoon and
radiofrequency current (RFC) groups calculated by multiplying
the number of HCUs by the specific payer cost per HCU across 3
national healthcare systems. The cryoballoon group demonstrated
a statistically significant cost reduction in all 3 systems when
compared with RFC, with the largest cost reductions in repeat
ablations and cardiovascular rehospitalizations. Cryo indicates
cryoballoon.
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patient cost differences translated to a significant reduction in
total costs between the 2 treatment groups: €245 000 in
Germany, £140 000 in the United Kingdom, and $355 000 in
the United States. The largest payer cost reductions were
observed for repeat ablations and cardiovascular rehospital-
izations.
Sensitivity Analysis
The results of the bootstrapping analysis are presented in
Figure 2. The distribution of estimated cost savings indicates
an extremely high likelihood of cryoballoon being cost saving
compared with RFC, with a 97% and 98% probability of cost
savings in the all-cause rehospitalization and cardiovascular
rehospitalization analyses. The results of the 1-way sensitivity
analyses are presented in Figure 3. The size of the cost
savings was most dependent on the payment level for a
repeat ablation (higher payment associated with higher cost
savings) and largely insensitive to changes in the individual
payment levels for other types of HCU.
Discussion
The primary analysis of FIRE AND ICE demonstrated
noninferiority, while the secondary end point analysis of
FIRE AND ICE, which included all events (both within the
blanking period and beyond a primary event) through study
exit, established that using cryoballoon for PVI results in
fewer HCUs than does RFC. The present economic analysis
demonstrates that this reduction in HCUs is robust enough
to manifest in significantly lower patient care costs from the
payer perspective, and this cost reduction persists across all
3 healthcare systems analyzed. Our analysis demonstrated
significant total cost savings during the trial period of €640
(P=0.012) in Germany, £364 (P=0.013) in the United
Kingdom, and $925 (P=0.016) in the United States. The
primary cost difference between cryoballoon and RFC was
the lower incidence of repeat ablation procedures in the
cryoballoon group, accounting for most of the total cost
difference between therapies. These cost savings are
strongly impacted by both a reduction in the probability of
repeat ablation procedures (33%) and by the high payer cost
of this HCU. The reduction in repeat ablations has been
observed in a prior study12 and is now confirmed in a large
randomized trial.
The annual number of AF ablation procedures for all AF in
the 3 countries evaluated is reported to be: 33 628 proce-
dures in Germany, 6 390 procedures in the United King-
dom,13 and 75 000 procedures in the United States.14 Given
the lower payer costs estimated in this study, if cryoballoon
All-cause rehospitalizations
Cardiovascular
rehospitalizations
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Figure 2. Cost-savings distribution: German healthcare system results of bootstrap modeling of 1000
healthcare utilization (HCU) iterations in the German healthcare system, with the y axis demonstrating
the frequency of cost savings and the x axis demonstrating the amount of cost savings. As demonstrated
by the distributions to the right of the dotted line, the cryoballoon (CB) group demonstrated cost savings
compared with the radiofrequency current (RFC) group, with 97% and 98% probability in the all-cause
rehospitalization and cardiovascular-only rehospitalization analyses, respectively.
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was used instead of RFC, significant payer cost savings would
be realized following index ablation. Exact savings calculations
would need to be performed by each payer organization,
incorporating the size of their respective paroxysmal AF
population and the current ratio of treatment by cryoballoon
versus RFC.
The reduction in repeat ablations and cardiovascular
rehospitalizations is important, from a clinical, biophysical,
and economic perspective. It indirectly reflects a decrease
in AF “burden” (the fewer AF recurrences, the fewer
interventions required). Thus, even though the AF burden
cannot be precisely determined in FIRE AND ICE (contin-
uous AF burden data were not collected), the number of
repeat ablations and direct-current cardioversions are a
valid surrogate for AF burden. The difference in repeat
ablations and cardioversions following cryoballoon or RFC
ablation can be explained by the different modes of lesion
formation associated with either technique. In brief, during
cryoballoon ablation, anatomical circumferential PVI is
achieved in a uniform “single shot” of coolant delivered
to the pulmonary vein antra by the cryoballoon. However,
during RF catheter ablation, PVI is achieved using a “point-
by-point” application of heat during serial focal ablations.
Previous evaluations of PVI at repeat procedures have
shown that the rate of pulmonary vein reconnection is
significantly lower following cryoballoon ablation (20.4%)
than following RFC ablation with contact-force sensing
catheters (36.1%).15 These data, when evaluated with other
published lesion durability studies reporting 37% of patients
with conduction gaps post RFC ablation16 and 22% of
patients with gaps post cryoballoon ablation,17 suggest that
the cryoballoon may be more effective in creating durable
transmural lesions.
The reduction in repeat ablations takes on additional
importance when considering the programs that payers have
implemented and plan to implement to deliver appropriate
care to their members with maximum efficiency. Several
European countries have implemented “budget envelopes,”
under which large increases in the spending associated with a
medical technology from year to year are not fully covered. If
the cost or number of procedures exceeds predefined levels,
payment rates are reduced for the additional procedures.
Other forms of risk sharing between payers and providers
(such as bundled payment for a year of care) are at various
stages of implementation but are intended to have a similar
effect. A health technology that can appropriately treat the
same number of patients with fewer overall claims could help
avoid negative economic consequences for patients, provi-
ders, and payers.
Cardiovascular rehospitalizations (not inclusive of repeat
ablation procedures) are also a meaningful driver of the cost
difference observed in this analysis. These rehospitalizations
are likely to have been driven by patients experiencing
recurring AF symptoms and seeking medical care. Noncar-
diovascular rehospitalizations are not a cost driver, and this is
likely because of the relative youth and health of the
€ 800
€ 750
€ 700
€ 650
€ 600
€ 550
€ 500
€ 450
€ 400
Repeat Ablation AF Rehospitalization Cardioversions
Figure 3. Sensitivity analysis on payment levels: German healthcare system. One-way sensitivity analysis
after varying the payment level for the most commonly used payment codes. The blue “x” indicates the
mean cost savings per patient from the analysis. The green and red arrows illustrate how the cost savings
change when the individual cost input is decreased or increased by 20%, respectively. The analysis
demonstrates that cost savings was most dependent on the payment for a repeat ablation and largely
insensitive to changes in the individual payment levels for other types of healthcare utilization. AF indicates
atrial fibrillation.
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paroxysmal AF population receiving ablations compared with
other cardiovascular disease. Cardioversions were not a
strong driver of costs in this analysis (because the event rate
was low compared with the other HCU types), but their impact
on hospital resource burden and patient experience cannot be
ignored. There was no difference in payer costs for the index
ablation procedure and associated hospitalization as payers
do not have a cost difference because reimbursement
between the 2 therapies is the same.
Although the present analysis was evaluated from the
payer perspective, it is important to consider implications for
other healthcare stakeholders. It should be acknowledged
that from the perspective of individual hospitals, costs to
perform catheter ablation, rehospitalizations, and reinterven-
tions may vary, based on factors such as total materials used,
pricing negotiations, electrophysiology laboratory staffing,
efficiency in electrophysiology laboratory utilization, and
length of stay.
From a hospital perspective under a fee-for-service
payment model, repeat ablations and other rehospitalizations
are reimbursed activities, reducing incentives to minimize
their occurrence. Healthcare payment reform is happening in
many countries around the world—for example, in the United
States, the Department of Health and Human Services has set
a goal of tying 50% of Medicare fee-for-service payments to
quality or value through alternative payment models by 2018.
These changes are intended to cause hospitals and payers to
share incentives to improve the quality and reduce the cost of
health care, including reducing the occurrence of HCUs. From
a patient perspective, depending on the insurance arrange-
ment, there may be a desire to reduce out-of-pocket expenses
associated with additional healthcare use.
Study Limitations
This economic analysis was a supplementary analysis not
prespecified in the FIRE AND ICE study protocol. It
represents differences in cost for hospital stays during
follow-up after an index AF catheter ablation procedure.
Diagnosis and procedure coding were imputed from the trial
data rather than being directly collected in the study;
however, this was based on information that was adjudi-
cated by an independent adverse event committee com-
posed of physician investigators. It is possible that
information that could have impacted cost assignments
was underreported. It was not possible to include all types
of resource use in this analysis because of the missing data
in the study, eg, medications and primary care visits.
Payment levels represent national tariffs/payments rather
than what an individual hospital would receive. The specific
care given to patients could vary between different health-
care systems, impacting outcomes and costs.
Conclusions
In symptomatic patients with drug-refractory paroxysmal AF,
de novo PVI using cryoballoon ablation was associated with a
reduction in HCU compared with RFC ablation. This reduction
resulted in substantial trial period cost savings to the payer,
which was attributable to the reduced need with cryoballoon
for repeat ablations and a reduction in cardiovascular
rehospitalizations. These cost savings persisted over multiple
healthcare systems.
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I n the article by Chun et al, “The Impact of CryoballoonVersus Radiofrequency Ablation for Paroxysmal Atrial
Fibrillation on Healthcare Utilization and Costs: An Economic
Analysis From the FIRE AND ICE Trial” which published online
July 27, 2017, and appeared in the August 2017 issue of the
journal (J Am Heart Assoc. 2017;6:e006043. DOI: 10.1161/
JAHA.117.006043.), there were errors found in Figure 1. On
page 5, Figure 1, “United Kingdom” and “United States” were
misspelled. The corrected figure is presented below.
The publisher regrets these errors.
The online version of the article has been updated and
is available at http://jaha.ahajournals.org/content/6/8/
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Figure 1. Healthcare cost savings: Total trial period payer costs
of healthcare utilizations (HCUs) for the cryoballoon and
radiofrequency current (RFC) groups calculated by multiplying
the number of HCUs by the specific payer cost per HCU across 3
national healthcare systems. The cryoballoon group demonstrated
a statistically significant cost reduction in all 3 systems when
compared with RFC, with the largest cost reductions in repeat
ablations and cardiovascular rehospitalizations. Cryo indicates
cryoballoon.
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